José Alexandre Crippa's 70 research works with citations and reads, including: Brazilian-Portuguese version of the José Alexandre S. Crippa. Semantic Scholar profile for José Alexandre S. Crippa, with highly influential citations. José Alexandre de Souza Crippa. Faculdade de Medicina de Ribeirão P Fusar -Poli, JA Crippa, S Bhattacharyya, SJ Borgwardt, P Allen, Archives of general.
Crippa S José Alexandre
The relationship between ethnicity and service access, treatment uptake and the incidence of psychosis among people at Ultra High Risk for Psychosis Byrne, M. Unmet needs in patients with brief psychotic disorders: Too ill for clinical high risk services and not ill enough for first episode services Minichino, A. Can we reduce the duration of untreated psychosis? A systematic review and meta-analysis of controlled interventional studies Oliver, D. Risk of readmission into secondary mental health services in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine Kesserwani, J.
Antipsychotic drug use and pneumonia: Systematic review and meta-analysis Dzahini, O. Journal of psychopharmacology Oxford, England. Predicting parkinsonism side effects of antipsychotic polypharmacy prescribed in secondary mental healthcare Kadra, G. Restrictions on drugs with medical value: Moving beyond stalemate Freeman, T. Language bias and comprehensive meta-analysis of folate for unipolar depression Taylor, M.
One of the corners of the arena has a shelter box with black walls and a complex maze inside. Three days prior to the experiment, the mice were placed and kept in this arena, with free access to food and water until the day of the trial. The "no threat" group had its behaviors recorded for five minutes.
The group of animals that were not confronted with the predator presented no defensive behaviors. Animals pre-treated with CBD had significant reductions in explosive flight and defensive immobility, responses related to panic models. Risk assessment and defensive attention were unaltered in animals treated with CBD. These results suggest that CBD can be effective in the control of panic attacks.
Based on this preliminary evidence, researchers decided to investigate a possible anxiolytic action of CBD in experimentally induced anxiety in healthy volunteers using the simulated public speaking SPS model. CBD mg , as well as the anxiolytic drugs diazepam 10 mg and ipsapirone 5 mg , administered in a double-blind design, significantly attenuated SPS-induced anxiety. The SPS test may be regarded as a good model of anxiety and has apparent validity for social anxiety disorder SAD , as the fear of speaking in public is considered a central feature in this condition.
Therefore, the anxiolytic effect of CBD in healthy volunteers observed in this test led to the hypothesis that this cannabinoid could be effective to treat SAD. This hypothesis was recently tested in 24 patients with SAD who had their performance in the SPS test compared to that of a group of 12 healthy controls. The results showed that the levels of anxiety, somatic symptoms, and negative self-assessment were higher in patients who took placebo than in those of the CBD group who performed similarly to healthy controls in some measures.
CBD significantly reduced subjective anxiety as measured by rating scales, while brain activity was increased in the left parahippocampal gyrus and decreased in the left amygdala-hippocampus complex, including the fusiform gyrus.
Functional magnetic resonance imaging fMRI , which allows the acquisition of larger series of images with better temporal and spatial resolution, was used to investigate the neural correlates of the anxiolytic effects of CBD in 15 healthy volunteers. The same group also reported that the anxiolytic action of CBD occurs by altering the subcortical prefrontal connectivity via amygdala and anterior cingulated.
Together, the results from laboratory animals, healthy volunteers, and patients with anxiety disorders support the proposition of CBD as a new drug with anxiolytic properties. Because it has no psychoactive effects and does not affect cognition; has an adequate safety profile, good tolerability, positive results in trials with humans, and a broad spectrum of pharmacological actions, 36 CBD appears to be the cannabinoid compound that is closer to have its preliminary findings in anxiety translated into clinical practice.
In addition, because the actions of CBD are biphasic, the adequate therapeutic window for each anxiety disorder remains to be determined. Regarding the mechanism underlying the anxiolytic effects of CBD, the most consistent evidence points to the involvement of the serotonergic system, probably through direct action on 5-HT1A receptors, although other systems, as the endocannabinoid system itself, may also be implicated.
Further investigation is warranted to clarify these issues, especially if we consider that CBD is a drug with a variety of effects in the nervous system. Chemical basis of hashish activity. Neurophysiologicaland subjective profile of marijuana with varying concentrationsof cannabinoids. Cannabidiol - recent advances. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. Antianxiety effect of cannabidiol in the elevated plus-maze. Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats.
Complex pharmacology of natural cannabinoids: Comparative receptor binding analyses of cannabinoid agonists and antagonists. Agonistic properties of cannabidiol at 5-HT1a receptors. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats.
Modulation of effective connectivity during emotional processing by Delta 9 -tetrahydrocannabinol and cannabidiol. Neural basis of anxiolytic effects of cannabidiol CBD in generalized social anxiety disorder: Comparative effects between cannabidiol and diazepam on neophobia, food intake and conflict behavior. Res Commun Psychol Psychiatry Behav. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther. Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids.
Prog Neuropsychopharmacol Biol Psychiatry. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test.
Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Cannabidiol chronic treatment attenuates panic-like responses via direct modulation of 5HT1A receptors functions in the dorsal periaqueductal grey matter. Molecular targets for cannabidiol and its synthetic analogues: Cannabidiol inhibitory effect on marble-burying behaviour: Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM and cannabidiol in conditioned rats.
Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats.
José Alexandre S. Crippa
Rafael Guimarães Dos Santos; José Alexandre Crippa; Flávia de Lima Osório Ila M. P. Linares · Francisco S. Guimaraes; Alan Eckeli; Ana C. S. Crippa. LINARES, ILA M. P.; BALARINI, FERNANDA B.; CHAGAS, NATALIA MOTA S.; TUMAS, VITOR; CRIPPA, JOSE ALEXANDRE S.. Can anxiety increase tremors. José Alexandre S. Crippa studies Humans, Young Adult, and Clinical Sciences.